share_log

中外薬---大幅続落、第1四半期は大幅減収決算に

Chugai Pharmaceutical --- drastic decline, with a drastic decline in sales in the first quarter

Fisco Japan ·  Apr 25 01:26

$Chugai Pharmaceutical (4519.JP)$has continued to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. They seem to have a negative view of sluggish headlines.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment